Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioversys Completes BV100 Phase 2 for Ventilator-Associated Pneumonia
Details : BV100 a novel formulation of rifabutin, being investigated in adults with ventilator associated bacterial pneumonia suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii.
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Bioversys Secures Investment For BV100 Clinical Program in China
Details : The company will expand the clinical development of its lead asset BV100, a novel formulation of rifabutin being developed for hospital infections caused by Acinetobacter baumannii, in China.
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 09, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GIBF2
Deal Size : $6.0 million
Deal Type : Financing
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
BioVersys Expands Collaboration with GSK and Extends Series C Round By CHF 12.3M
Details : Proceeds will enable the clinical development of BioVersys’ portfolio, including BV100 (rifabutin), a breakthrough antibiotic targeting Acinetobacter baumannii, a highly resistant bacterial pathogen.
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 05, 2024
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : $49.5 million
Deal Type : Series C Financing
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
AMR Action Fund Announces Investment in BioVersys AG
Details : BioVersys' lead candidate, BV100 (rifabutin), is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : BioVersys AG
Deal Size : Undisclosed
Deal Type : Collaboration
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
Details : BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstrea...
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 25, 2022
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : BioVersys AG
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100
Details : BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.
Product Name : BV100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : Rifabutin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable